201 studies found for:    Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan
Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Myelogenous Leukemia, Chronic, Chronic Phase
Intervention:
2 Unknown  Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Medication Adherence
Interventions: Behavioral: Adherence-encouraging interventions - Group meeting;   Behavioral: Adherence-encouraging interventions - Individual meetings;   Behavioral: Adherence-encouraging interventions - Monthly phone calls
3 Not yet recruiting Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions: Drug: Pioglitazone;   Drug: imatinib mesylate
4 Not yet recruiting Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Conditions: Chronic Myelogenous Leukemia;   Chronic Myeloid Leukemia;   Leukemia
Interventions: Drug: Dasatinib;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Other: Questionnaire Administration
5 Recruiting A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: ponatinib 30 mg QD;   Drug: ponatinib 15 mg QD;   Drug: nilotinib 400 mg BID
6 Recruiting Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib
7 Recruiting Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pioglitazone Hydrochloride;   Drug: Tyrosine Kinase Inhibitor (TKI)
8 Recruiting Regional Central Database Recording of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: Practices evaluation
9 Not yet recruiting Bosutinib in Elderly Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Bosutinib
10 Recruiting Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
Condition: Chronic Myeloid Leukemia
Intervention: Behavioral: Dasatinib discontinuation
11 Recruiting Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
Condition: Chronic Phase Chronic Myeloid Leukemia
Intervention: Drug: P1101
12 Recruiting Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Condition: Chronic Myelogenous Leukemia
Intervention: Other: Chart Review
13 Recruiting Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
Conditions: Chronic Phase Philadelphia Positive;   BCR-ABL Positive;   Chronic Myeloid Leukaemia
Intervention:
14 Recruiting TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib/Nilotinib
15 Recruiting Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Conditions: Chronic Phase Chronic Myeloid Leukemia;   Accelerated Phase Chronic Myeloid Leukemia;   Blastic Phase Chronic Myeloid Leukemia;   Philadelphia Positive Acute Lymphoblastic Leukemia;   Resistant to Tyrosine Kinase Inhibitor Therapy
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
16 Recruiting LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients
Condition: Chronic Myeloid Leukemia
Intervention: Other: QoL Survey Booklet
17 Recruiting Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Condition: Philidelphia Positive Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib
18 Recruiting Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Imatinib
19 Recruiting Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)
Conditions: Leukemia;   Chronic Myeloid Leukemia;   Myelofibrosis
Intervention: Drug: Eltrombopag
20 Recruiting Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years